The adoption of nintedanib in systemic sclerosis: the SENSCIS study

Nintedanib shows a statistically significant effect on lung function decay in patients with ILD secondary to systemic sclerosis, but no effect on skin fibrosis and on health-related quality of life http://bit.ly/2vfJRj7

Detalles Bibliográficos
Autores principales: Bruni, Teresa, Varone, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Expert Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341613/
https://www.ncbi.nlm.nih.gov/pubmed/32665787
http://dx.doi.org/10.1183/20734735.0005-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341613/
https://www.ncbi.nlm.nih.gov/pubmed/32665787
http://dx.doi.org/10.1183/20734735.0005-2020

Ejemplares similares